Дивигель

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Дивигель

Quick Facts

Property Description
Active ingredient Estradiol Hemihydrate
Form Transdermal Gel (Гель)
Pharmacological class Estrogen replacement therapy (ERT)
Common use Counteracting Estrogen deficiency
Origin Bioidentical (structurally) / Synthetic (preparation)

What Type of Medicine is Дивигель and How is it Classified?

Дивигель is a prescription-only medicinal product classified as an Estrogen Derivative and utilized as Estrogen replacement therapy (ERT), falling within the comprehensive group of Hormone replacement therapy (HRT). Its active component is Estradiol Hemihydrate, a substance whose pharmacological importance is clinically recognized for managing hormone deficit states. The Estradiol in Дивигель is chemically bioidentical to the primary Endogenous Estrogen produced by the human body, though it is supplied in a synthetic, micronized form for pharmaceutical application. As a single active ingredient product (monotherapy), its primary role is to supplement the specific hormone that the body is no longer producing adequately.

What is the Composition of Дивигель and What Form Does it Take?

The medicine is uniquely formulated as a clear, hydroalcoholic Transdermal Gel (Гель) intended for topical application onto the skin. This specialized Dosage form is a key differentiating factor, utilizing the skin as the entry point for the active component, micronized Estradiol Hemihydrate, which is suspended in a base containing ethanol and purified water. This enables the transdermal route of administration, which is pharmacologically preferred in many cases because it facilitates direct absorption into the systemic circulation, thereby minimizing the extensive initial metabolism, or first-pass effect, encountered with oral hormone derivatives. This delivery system is designed to provide a steady, predictable supply of the hormone.

What is the General Purpose of Estradiol Replacement Therapy?

The general purpose of using Дивигель is the targeted replacement of Estrogen to directly counteract the fundamental state of Estrogen deficiency that develops in Postmenopausal women. The therapeutic effect relies on the Endocrine-metabolic action of Estradiol, where the absorbed hormone binds to Estrogen Receptors (ER) throughout the body, helping to restore the biological functions regulated by this crucial hormone. A typical application is for women experiencing vasomotor symptoms; the therapy helps to stabilize the patient's endocrine profile by supplementing inadequate levels of Endogenous Estrogens.

What side effects are possible with Дивигель?

Possible Side Effects and Safety Information

The safety profile of Estradiol Transdermal Gel (Дивигель) is established through regulatory classifications that organize adverse reactions by frequency and organ system. The spectrum of effects ranges from common, generally non-serious reactions to rare, serious adverse events associated with systemic Estrogen Replacement Therapy (ERT).

Frequency-Classified Adverse Reactions

Classification Examples of Documented Effects
Very Common Headache, Back pain, Arthralgia (joint pain).
Common Nausea, Abdominal pain, Bloating, Breast tenderness, Application site irritation, Dizziness, Weight changes.

Adverse effects are officially grouped by System-Organ Classes, including the Reproductive System and Breast (e.g., metrorrhagia, breast pain) and Nervous System (e.g., migraine, headache).

Serious Adverse Reactions

Official labeling documents emphasize rare but serious risks associated with systemic estrogen use. These include an increased risk of Venous Thromboembolism (blood clots, such as Deep Vein Thrombosis and Pulmonary Embolism), Stroke, and Myocardial Infarction. Furthermore, use is associated with an increased risk of certain Malignancies, specifically endometrial cancer (in women with an intact uterus) and breast cancer.

Population-Specific Safety Considerations

The regulatory profile includes specific notes for certain groups. For women ge 65 years, an increased risk of probable dementia is documented. The product is officially contraindicated in conditions such as known liver disease, active thromboembolic disorders, and a history of certain estrogen-dependent cancers. For women with an intact uterus, a progestin must be co-administered to mitigate the risk of endometrial hyperplasia and carcinoma.

Overdose and Emergency Response

Suspected overdose with Estradiol Hemihydrate Transdermal Gel requires immediate action, as mandated by regulatory authorities. The acute manifestations of excessive exposure, known as hyperestrogenism, are documented to include non-life-threatening symptoms such as nausea, vomiting, and breast tenderness. Other documented clinical signs may involve headache, fluid retention, dizziness, and abdominal pain. A specific, delayed presentation is the occurrence of excessive vaginal bleeding (withdrawal bleeding), which can manifest days after the overexposure event. Regulatory information classifies the risk of serious acute outcomes as very unlikely.

Mandated Emergency Response

In the event of a suspected overdose, official guidance instructs individuals to contact a poison control center or emergency room at once. The primary management for overdose is symptomatic and supportive treatment, which includes immediate discontinuation of the medication. While activated charcoal may be considered in extreme cases, the overall approach focuses on symptom relief and observation. Medical personnel may monitor vital signs and may perform blood and urine tests. Urgent emergency services (e.g., calling 911) are required only if the individual experiences serious symptoms such as passing out or trouble breathing.

Therapeutic Uses of Дивигель

The therapeutic application of this medicine is applied in addressing symptoms related to Estrogen deficiency that arise during menopause. The medicine is considered relevant across three main symptomatic and long-term therapeutic domains. It is generally considered relevant for managing moderate to severe vasomotor symptoms, urogenital atrophy, and is applied in managing the risk of postmenopausal osteoporosis in relevant contexts.

Symptom Management and Patient Benefits

This therapy is commonly used to address symptom clusters that interfere with daily comfort during menopause, providing symptomatic support aimed at contributing to easing the overall symptom load of frequent and intense hot flashes and bothersome night sweats. The therapy supports general well-being by supporting stable functioning and contributing to easing overall discomfort. It is also used for managing symptoms related to Urogenital Atrophy, including chronic vaginal dryness, irritation, and painful sexual activity (dyspareunia). This application offers the practical benefit of supporting tissue comfort and functional stability, assisting with easing patient distress and supporting general well-being during symptomatic phases.

Regarding the overall experience of this hormonal transition, the therapy may assist with maintaining functional stability when symptoms fluctuate.

“This approach supports general well-being during symptomatic phases and assists with mitigating risks associated with postmenopausal bone loss.”


Quick Fact: Symptom Clusters

Property Description
Primary Focus Vasomotor Symptoms (e.g., hot flashes, night sweats)
Secondary Focus Urogenital Atrophy (e.g., dryness, irritation)
Long-Term Benefit Management of Postmenopausal Osteoporosis risk
Use Context Conditions characterized by periods of heightened symptoms

Eligibility and Restrictions for Use

Population Eligibility for Divigel (Estradiol Gel)

Official regulatory documents state that Divigel is primarily indicated for use in postmenopausal women for specific therapeutic purposes. Use is strictly defined by patient history, age, and pre-existing conditions.


Contraindications (Absolute Ban)

The medicine is contraindicated and must not be used in women with the following conditions:

  • Known, suspected, or history of breast cancer or estrogen-dependent neoplasia.
  • Active or history of arterial thromboembolic disease (e.g., stroke, MI) or venous thromboembolism (DVT, PE).
  • Undiagnosed abnormal genital bleeding.
  • Acute liver disease or severe impairment.
  • Known or suspected pregnancy or while breastfeeding.

Restricted and Non-Eligible Groups

Category Eligibility Rule
Intact Uterus Requires mandatory progestogen co-treatment to reduce the risk of endometrial overgrowth.
Pediatric Use Not indicated; safety and efficacy have not been established.
Older Adults Use is limited; labeling notes caution for women over 65 based on findings from oral hormone therapy trials.
Comorbidities Conditions like hypertension, diabetes, and uterine fibroids require close medical supervision during treatment.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This section summarizes the officially documented interaction profile for Дивигель (Estradiol Hemihydrate Gel) as defined in government regulatory information, focusing strictly on how other substances affect the medication or vice-versa.

Metabolic and Exposure Alterations

Interaction Type Interacting Substances (Examples) Official Effect
Reduced Exposure CYP3A4 Inducers: Phenobarbital, Rifampin, St. John's Wort May reduce Estradiol plasma concentrations and therapeutic effect.
Increased Exposure CYP3A4 Inhibitors (General Class) May increase Estradiol plasma concentrations.

The core of the pharmacokinetic profile involves the enzyme Cytochrome P450 3A4 (CYP3A4); agents that induce or inhibit this enzyme are documented to alter the systemic exposure to Estradiol.

Pharmacodynamic and Procedural Constraints

  • Thyroid Replacement Therapy: Estradiol can increase Thyroid-binding globulin (TBG) levels, necessitating the monitoring of thyroid function for women receiving replacement therapy.
  • DAA Agents: Warnings exist regarding the co-administration of Estradiol with certain Direct Acting Antiviral (DAA) agents used for Hepatitis C.
  • Topical Timing: The official label advises a minimum 25-minute separation between applying Дивигель and applying sunscreen to the same skin area.
  • Physical Contact: A caution exists regarding the risk of transdermal transfer of the active ingredient to others, especially children, following physical contact with the application site.

Mechanism of Action

Receptor Agonism and Dual Signaling

The core mechanism involves the active ingredient, estradiol, acting as a full agonist that binds to and activates Estrogen Receptors ( ERalpha, ERbeta, and GPER1). This initiates two distinct signaling cascades: a slower genomic cascade that alters gene transcription in the cell nucleus, and a rapid non-genomic cascade that triggers fast signals from the cell membrane. This dual activation mediates estrogen-dependent cellular signaling and sustained protein synthesis throughout the body.

Systemic and Central Nervous System Modulation

Estradiol exerts a significant modulatory influence on key regulatory systems. It specifically acts within the Central Nervous System ( CNS) to modulate the hypothalamic thermoregulatory center, which controls body temperature. Peripherally, it influences the bone remodeling pathway by adjusting cell activity and modulates the function of the vascular endothelium. These actions influence the thermal set point and modulate skeletal and vascular tissue processes.

Dosage and Administration Information

Administration Protocol and Dosing

Дивигель (estradiol gel) is administered exclusively via the transdermal route for systemic hormone replacement. The gel is applied once daily to a clean area of skin, such as the lower trunk or thigh, with the site of application being alternated each day. The dose must be allowed to dry completely before clothing is worn, and the application area must not be washed for at least one hour.

For women who have an intact uterus, concurrent treatment with a progestagen is required for a minimum of 12 to 14 consecutive days per 28-day cycle.


Administration Scope

Feature Instruction
Dosing Schedule Starting dose typically ranges from 0.25 mg estradiol per day to 1.0 mg per day, with a maximum permitted daily dose of 1.5 mg estradiol. The dosage is adjusted clinically after initial treatment cycles.
Frequency Once daily.
Missed-Dose Rule If a dose is forgotten, it should be applied as soon as the user remembers, unless it is already time for the next dose; double dosing is strictly prohibited.

Resulting Procedural Structure

Administration instructions include:

  • Applying the unit-dose contents to a non-irritated area of the thigh or lower trunk.
  • Alternating the application site on consecutive days.
  • Washing hands thoroughly after use.
  • Strictly not applying the gel to the breasts, face, or irritated skin.

Connection to the overall use protocol: These instructions define a standardized, once-daily topical regimen with specific requirements for application and post-application hygiene. The protocol further outlines a mandatory co-administration schedule for a progestagen in patients with an intact uterus, thereby structuring the full hormone replacement regimen.

Recent Clinical Evidence

Research Evidence / Overview of studies for Divigel

Evidence for use in Chronic Insomnia

Structured clinical trials have explored the agent in relation to measured sleep outcomes in adults with chronic insomnia. Research monitored physiological strain outcomes, such as sleep latency (time to fall asleep) and total sleep duration, usually over short time intervals. Findings describe group patterns observed in the studies, including measurements related to a shorter time taken to fall asleep. However, the data show patterns varied across the different trials, and long-term data for this indication are not well-characterized. Based on the available research, certainty remains low regarding sustained patterns observed beyond the immediate study periods.

Evidence for use in Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)

The agent was studied in randomized controlled trials for both MDD and GAD. Research examined outcomes related to daily functioning by monitoring standardized symptom rating scales (e.g., HAM-D, HAM-A) to understand short-term changes. Findings indicate patterns such as changes in average symptom scores reported on these scales during the observation periods. Evidence is limited for both indications, and findings were mixed regarding evaluation as a sole treatment versus alongside other treatments. These study results reflect the specific conditions under which they were conducted.

What is still uncertain about Divigel

Across all studied indications, key gaps exist in the research landscape. Long-term patterns are not fully established, as follow-up durations were limited in most existing studies. Sample sizes were often modest, meaning the results apply only to the populations studied. Data remain insufficient for certain special groups, such as children, adolescents, or older adults, and comparative evidence against other established treatments is lacking. Research provides context about what has been observed so far, but findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Дивигель (FAQ)

Q: Is there a risk of the gel transferring to my partner or children after application?

Yes, regulatory documents include a caution about the potential for Estradiol Transfer through skin-to-skin contact. This is because others, especially children, could be exposed to the medication. Following the recommended application and hygiene steps is essential to prevent this accidental exposure.


Q: What steps should I take to prevent Дивигель transfer to others?

To reduce the risk of transfer, regulatory guidance recommends that the application site must be allowed to dry completely before any skin-to-skin contact. The site should then be covered with clothing, and the user must wash their hands thoroughly with soap and water immediately after applying the medication.


Q: How long does the gel take to dry completely after application?

Official administration instructions require that the gel must dry completely before dressing. Information regarding similar transdermal estrogen gels suggests that the product typically dries on the skin within a few minutes after application, but the priority is confirming it is fully dry.


Q: Should I wait a certain amount of time after applying Дивигель before exercising or swimming?

Yes, official regulatory documents advise not washing the application site within 1 hour after applying the gel. This time frame also applies to activities such as swimming or exercise that cause heavy sweating, which could interfere with the full absorption of the medication into the body.


Q: Can I apply sunscreen or moisturizer on the same area where I use Дивигель?

The official labeling includes a warning regarding the use of other topical solutions near the application area. Caution is advised regarding the application of products like sunscreen or moisturizer, as they may alter the way the Estradiol is absorbed from the gel. Patients are generally advised to discuss the use of other products with their healthcare provider.


Q: Does alcohol consumption affect how Дивигель works?

The gel is a hydroalcoholic formulation and is flammable until dry, requiring avoidance of fire, flame, or smoking near the application site. The direct effect of moderate alcohol consumption on systemic absorption is not consistently defined in the core regulatory documents, but patients who consume alcohol should discuss their use with a healthcare provider.


Q: Is it true that the gel must be fully dry before putting on clothes?

Yes, official instructions explicitly advise allowing the gel to dry completely after application before dressing. This is a procedural requirement intended to help ensure the full dose of the medication is absorbed by the skin and to prevent it from rubbing off onto clothing.


Q: Is transdermal gel (like Дивигель) considered safer than oral estrogen tablets?

The FDA Boxed Warning applies to all systemic estrogen therapy. Transdermal forms are thought to affect the risk profile for venous thromboembolism (blood clots) differently compared to oral estrogen formulations. The official product information states that all systemic estrogen therapy carries similar serious risks, but the delivery method may alter the VTE risk profile.


Q: How long can a woman safely use Дивигель?

Regulatory documents advise that the therapy should be used at the lowest effective dose for the shortest duration that is consistent with the patient's treatment goals and risks. The need for continued treatment must be reviewed regularly by a healthcare professional.


Q: What is the recommended timing for re-evaluating the need for Дивигель treatment?

Official guidance advises that patients should be reevaluated periodically to determine if treatment is still necessary. This often means the first follow-up visit should occur within 3 to 6 months of starting treatment, with reevaluation at regular intervals thereafter.


Q: Is Дивигель used for purposes other than menopause symptoms?

According to the official product information, Дивигель is indicated only for the treatment of moderate to severe vasomotor symptoms (such as hot flashes) that are a result of menopause. It is not approved for any other use.


Q: How quickly do most patients notice an improvement in hot flashes after starting Дивигель?

Clinical trial data indicate that a reduction in the frequency and severity of hot flashes was observed after 12 weeks of continuous treatment compared to placebo. While some individuals may notice earlier changes, individual response times may vary.


Q: What happens if I forget to apply Дивигель one day?

The official missed-dose rule instructs that if the next dose is less than 12 hours away, the dose should be skipped and the normal schedule resumed. If it is more than 12 hours until the next dose, the missed dose should be applied right away, and the normal schedule resumed the next day. Double dosing is prohibited.


Q: Can Дивигель cause or worsen existing migraine headaches?

Headache is listed as a very common side effect, and migraine is listed as an adverse reaction in the product information. Patients with a history of migraines should discuss this pre-existing condition with a healthcare provider, as the medication may be associated with these symptoms.


Q: What types of unexplained or abnormal bleeding are concerning when using Дивигель?

The medication is contraindicated in women who have undiagnosed abnormal genital bleeding. For women who still have a uterus, any persistent or recurring abnormal genital bleeding requires prompt medical investigation to rule out serious conditions, including malignancy.


Q: Is there a higher risk of blood clots with Дивигель compared to other HRT forms?

The FDA Boxed Warning indicates that all systemic estrogen therapy increases the risk of Venous Thromboembolism (VTE). While studies suggest differences in VTE risk between transdermal and oral forms, the overall serious risk associated with VTE is a key component of the official product information for all systemic estrogen therapy.


Q: Does the application site need to be rotated, and why?

Yes, official regulatory instructions advise applying the gel to the right or left upper thigh on alternating days. This practice is included in the prescribing information to help prevent potential skin irritation that can sometimes occur at the site of application.


Q: Can I use Дивигель if I have a history of uterine fibroids or endometriosis?

The official labeling notes that estrogen may exacerbate (worsen) endometriosis and stimulate the growth of uterine fibroids. Use in women with these specific conditions requires close medical supervision and monitoring, but it is not an absolute prohibition.


Q: What should I do if the gel accidentally gets into my eyes or mouth?

If the gel accidentally gets into the eyes, the instructions advise that they should be rinsed right away with warm water. In the event of accidental ingestion, such as the gel getting into the mouth, seeking medical attention is required.


Q: Is there a link between Дивигель use and changes in vision or contact lens comfort?

The official product information lists Eye Disorders as an adverse reaction observed after marketing, which includes visual disturbances and intolerance to contact lenses. Changes such as the steepening of the corneal curvature have also been noted.


Q: How does the efficacy of Дивигель for hot flashes compare across its different strengths?

Clinical studies examined three doses and showed that all doses resulted in a significant reduction in hot flash frequency and severity compared to placebo. Efficacy is generally related to the dose strength used, and the clinical studies demonstrated significant reductions in hot flash frequency and severity compared to placebo for all doses tested.


Q: If I have a history of high triglycerides, can I use Дивигель?

The official labeling includes a warning that estrogens may cause elevations in serum triglyceride levels, especially in women with pre-existing high levels. Therefore, use requires close medical monitoring, and treatment should be discontinued if severely elevated triglycerides lead to pancreatitis.


Q: Does Дивигель affect my body's natural production of estrogen?

The medication is a replacement therapy that delivers exogenous estradiol, which then supplements the body's deficient hormone levels. As with other hormone therapies, it works by introducing a steady amount of hormone to the body, which then influences the overall system of natural hormone regulation.


Q: What is the difference between Дивигель and a vaginal estrogen cream?

Дивигель is a transdermal gel applied to the skin for systemic treatment, meaning it affects the entire body and is used for symptoms like hot flashes. Vaginal estrogen creams are typically used for local treatment of vaginal and vulvar symptoms, as they target only the local tissues and not the whole body.

How should Дивигель be stored and disposed of?

How to Store and Dispose of Divigel (Estradiol Gel)

The storage and disposal of Divigel must strictly follow regulatory documentation to maintain product stability and ensure safety.

Storage Conditions

Divigel must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be kept in its original container and must be stored away from open flame. For safety, Divigel and all medications must be kept out of the sight and reach of children.

Disposal Requirements

Disposal procedures are mandated to protect the environment. It is prohibited to flush the gel down the toilet or pour it down a drain. Used and unused sachets must be carefully folded, placed into a container with a lid, and then discarded in the regular household trash. Unused or expired medicine should be taken to local drug take-back programs if available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Дивигель found in:

A-Z Index: